Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia.

被引：0

作者：

Hogdal, Leah ^{[1
]}

Chyla, Brenda ^{[2
]}

McKeegan, Evelyn ^{[2
]}

Leverson, Joel ^{[2
]}

Potluri, Jalaja ^{[2
]}

Humerickhouse, Rod ^{[2
]}

Mack, Mabry ^{[3
]}

DeAngelo, Daniel ^{[1
]}

Galinsky, Ilene ^{[1
]}

Stone, Richard ^{[1
]}

Letai, Anthony ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] AbbVie Inc, N Chicago, IL USA

[3] AbbVie Inc, Redwood City, CA USA

来源：

CLINICAL CANCER RESEARCH | 2015年 / 21卷

关键词：

D O I：

10.1158/1557-3265.HEMMAL14-B10

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B10

引用

页数：2

共 50 条

[1] BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia
Pan, Rongqing
Debose, LaKeisha
Benito, Juliana M.
Golfman, Leonard S.
Zweidler-McKay, Patrick A.
Han, Lina
Harutyunyan, Karine G.
Mu, Hong
Ruvolo, Vivian R.
Park, Eugene
Muschen, Markus
Leverson, Joel
Borthakur, Gautam
Kantarjian, Hagop M.
Ruvolo, Peter P.
Andreeff, Michael
Konopleva, Marina
BLOOD, 2013, 122 (21)
[2] BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia
Hogdal, Leah
Chyla, Brenda
McKeegan, Evelyn
Leverson, Joel
Potluri, Jalaja
Falotico, Nancy
Ricker, Justin
Humerickhouse, Rod
Mabry, Mack
Foight, Glenna
Keating, Amy
Galinsky, Ilene
Stone, Richard
DeAngelo, Daniel
Konopleva, Marina
Letai, Anthony
CANCER RESEARCH, 2015, 75
[3] BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia
Hogdal, Leah
DeAngelo, Daniel J.
Stone, Richard M.
Gaidzik, Verena I.
Bucci, Donna
Doehner, Konstanze
Marcucci, Guido
Ryan, Jeremy
Letai, Anthony
BLOOD, 2013, 122 (21)
[4] Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer
Lindeman, G. J.
Vaillant, F.
Merino, D.
Lee, L.
Breslin, K.
Pal, B.
Ritchie, M. E.
Smyth, G. K.
Christie, M.
Phillipson, L. J.
Burns, C. J.
Mann, G. B.
Visvader, J. E.
CANCER RESEARCH, 2013, 73
[5] Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Vaillant, Francois
Merino, Delphine
Lee, Lily
Breslin, Kelsey
Pal, Bhupinder
Ritchie, Matthew E.
Smyth, Gordon K.
Christie, Michael
Phillipson, Louisa J.
Burns, Christopher J.
Mann, G. Bruce
Visvader, Jane E.
Lindeman, Geoffrey J.
CANCER CELL, 2013, 24 (01) : 120 - 129
[6] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang
Chaitanya Iragavarapu
John Savooji
Yongping Song
Delong Liu
Journal of Hematology & Oncology, 8
[7] Arsenic Trioxide Synergistically Enhances the Antileukemia Activity of Bcl-2 Inhibitor ABT-199 in Acute Myeloid Leukemia
Liu, Sha
Chen, Lin
Wang, Xiaojiao
Mi, Ruihua
Yin, Qingsong
Fan, Ruihua
Wei, Xudong
BLOOD, 2019, 134
[8] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, Shundong
Iragavarapu, Chaitanya
Savooji, John
Song, Yongping
Liu, Delong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
[9] Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, Rongqing
Hogdal, Leah J.
Benito, Juliana M.
Bucci, Donna
Han, Lina
Borthakur, Gautam
Cortes, Jorge
DeAngelo, Daniel J.
Debose, LaKeisha
Mu, Hong
Doehner, Hartmut
Gaidzik, Verena I.
Galinsky, Ilene
Golfman, Leonard S.
Haferlach, Torsten
Harutyunyan, Karine G.
Hu, Jianhua
Leverson, Joel D.
Marcucci, Guido
Mueschen, Markus
Newman, Rachel
Park, Eugene
Ruvolo, Peter P.
Ruvolo, Vivian
Ryan, Jeremy
Schindela, Sonja
Zweidler-McKay, Patrick
Stone, Richard M.
Kantarjian, Hagop
Andreeff, Michael
Konopleva, Marina
Letai, Anthony G.
CANCER DISCOVERY, 2014, 4 (03) : 362 - 375
[10] The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C Touzeau
C Dousset
S Le Gouill
D Sampath
J D Leverson
A J Souers
S Maïga
M C Béné
P Moreau
C Pellat-Deceunynck
M Amiot
Leukemia, 2014, 28 : 210 - 212

← 1 2 3 4 5 →